ENTPD1 Recombinant Monoclonal Antibody

說明書

中文名稱：

ENTPD1重組抗體
貨號：

CSB-RA007690MA1HU
規格：

￥1320
圖片：
IHC image of CSB-RA007690MA1HU diluted at 1:100 and staining in paraffin-embedded human placenta tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-Human IgG labeled by HRP and visualized using 0.05% DAB.
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品描述：

CSB-RA007690MA1HU是針對ENTPD1（CD39）靶點開發的高特異性重組單克隆抗體，適用于酶聯免疫吸附（ELISA）和免疫組化（IHC）實驗。ENTPD1是一種胞外核苷酸水解酶，通過催化ATP/ADP水解為AMP調控嘌呤能信號通路，在免疫調節、腫瘤微環境及炎癥反應中發揮重要作用。本抗體經多種實驗驗證，在IHC應用中可清晰定位石蠟包埋組織中ENTPD1的蛋白表達，推薦使用1:50-1:200稀釋比例，其高親和力與低交叉反應性確保了實驗結果的可靠性。該產品適用于腫瘤免疫微環境分析、免疫細胞功能研究及炎癥性疾病機制探索等科研領域，為研究CD39在Treg細胞介導的免疫抑制、腫瘤免疫逃逸及自身免疫病理過程中的作用提供了優質工具。通過嚴格的質控體系，確保不同批次間穩定性，滿足精準檢測需求。
Uniprot No.：

P49961
基因名：

ENTPD1
別名：

ENTPD1 Recombinant Monoclonal Antibody
反應種屬：

Human
免疫原：

Recombinant Human ENTPD1 protein
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

hIgG1
純化方式：

Affinity-chromatography
克隆號：

5D3
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

In the nervous system, could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. Could also be implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. Hydrolyzes ATP and ADP equally well.
基因功能參考文獻：
1. Changes in the local expression and activity of CD39 and CD73 in calcified valves suggest their potential role in calcific aortic valve disease. PMID: 30056298
2. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. PMID: 30006565
3. CD39 expression and activity is attenuated in lung tissue of chronic obstructive pulmonary disease patients. PMID: 29807526
4. monocyte-derived macrophages from ankylosing spondylitis patients expressed reduced levels of CD39 mRNA compared to those from healthy controls PMID: 29524036
5. expression in primary lesions and metastatic lymph nodes seems to identify patients at high risk in squamous cell carcinoma of the head and neck PMID: 29172836
6. ur results demonstrate that CD39 is upregulated on conventional CD4+ and CD8+ T cells at sites of acute infection and inflammation, and that CD39 dampens responses to bacterial infection. PMID: 29742141
7. this paper shows that simultaneous overexpression of human E5NT and ENTPD1 protects porcine endothelial cells against H2O2-induced oxidative stress and cytotoxicity in vitro PMID: 28389406
8. The peripheral blood mononuclear cells (PBMC) from the transgenic pigs were more resistant to lysis by pooled complement-preserved normal human serum than that from wild type (WT) pig. Accordingly, GGTA1 mutated piglets expressing hCD39 will provide a new organ source for xenotransplantation research PMID: 27830476
9. Phosphoantigens (pAgs) induced expression of the ecto-ATPase CD39, which, however, not only hydrolyzed ATP but also abrogated the gammadelta T cell receptor (TCR) agonistic activity of self and microbial pAgs. PMID: 27346340
10. These studies showed that the G allele of rs3176891 marks a haplotype associated with increased clotting and platelet aggregation attributable to a promoter variant associated with increased transcription, expression, and activity of NTPDase1. PMID: 28302652
11. Transgenic expression of human CD39 is associated with increased renal fibrosis after ischemia in mice. PMID: 28198766
12. CD39 overexpression protects against cerebral ischemia in a transgenic mouse model. PMID: 28377485
13. Ablation of CD73 minimally effects in vivo thrombosis, but increased CD39 expression on hematopoietic-derived cells, especially monocytes, attenuates in vivo arterial thrombosis. PMID: 27417582
14. Data show that Th17(CD39+) cells are markedly diminished and fail to generate AMP/adenosine, thereby limiting control of both target cell proliferation and IL-17 production in juvenile autoimmune liver disease (AILD). PMID: 27210814
15. concluded that CD39 and CD73 are molecular targets for the development of drugs for ALF patients care PMID: 27899277
16. Oxidized low density lipoproteins modulate CD39 and CD73 activity in the endothelium. PMID: 27906627
17. this study shows that T-cell expression of CD39 was higher in acute exacerbations of chronic obstructive pulmonary disease patients than stable COPD patients or healthy controls PMID: 27430193
18. Pulmonary CD39 expression and activity are increased in COPD. Following acute cigarette smoke exposure CD39 was upregulated in BALF cells in smokers. PMID: 26541524
19. This study aimed to investigate the activities of purinergic system ecto-enzymes present on the platelet surface as well as CD39 and CD73 expressions on platelets of sickle cell anemia treated patients. PMID: 27044834
20. Increased inducibility of CD39 after activation may contribute to the impaired vaccine response with age. PMID: 26832412
21. The altered function and expression of P2X7 and ART1 in the human CD39+ Treg or CD39- Treg cells could participate in the resistance against cell death induced by ATP or NAD. PMID: 26307000
22. Despite the increased level of NTPDase1 and NTPDase3 mRNA expression in chondrogenically induced MSCs, their activity toward ATP remains quite low. PMID: 26018728
23. the expression of CD39 on Treg cells and also in CD4(+)IL-17(+) cells from T2D patients is related to hyperglycemia as well as to overweight and obesity and therefore may participate as a modulator of the effector capacity of Th17 cells. PMID: 26386144
24. We suggest modulation of human Th17 responsiveness by CD39 and CD161 and describe novel molecular mechanisms integrating elements of both extracellular nucleotide and sphingolipid homeostasis--{REVIEW} PMID: 26059452
25. Findings provide insights into Tc1-mediated IFNgamma responses and ROS generation and link these pathways to CD39/adenosine-mediated effects in immunological disease. PMID: 26549640
26. the current study revealed that malignant epithelial cells of human rectal adenocarcinoma strongly express CD39 that may play a potential role in the tumor invasion and metastasis. PMID: 26113408
27. role of CD73 and CD39 ectonucleotidases in T cell differentiation PMID: 26226423
28. this study demonstrates that the expression of CD39 in Tregs is primarily genetically driven, and this may determine interindividual differences in the control of inflammatory responses. PMID: 25640206
29. these data establish CD39 as a regionalized regulator of atherogenesis that is driven by shear stress. PMID: 26121751
30. our data indicate that T-cell CD39 expression may identify subsets of patients with B-CLL with an unfavorable clinical outcome. PMID: 24684231
31. The Na-K-2Cl cotransporter was downregulated by high-sodium diet in wild-type mice, but it increased in transgenic mice overexpressing human CD39 PMID: 25877509
32. apelin, a known regulator of pulmonary vascular homeostasis, can potentiate the activity of CD39 both in vitro and in vivo PMID: 25820525
33. Blackcurrant leaf extract increases endothelial cell NOS and CD39 levels in a concentration dependent manner. PMID: 25407137
34. Data show that Rubus leave extracts significantly increased CD39 antigen NTPDase 1 ecto-ATP diphosphohydrolase 1 (CD39/NTPDase-1) expressions and decreased ATPDase activities. PMID: 25034034
35. Low expression of CD39(+) /CD45RA(+) on regulatory T cells (Treg ) cells in type 1 diabetic children in contrast to high expression of CD101(+) /CD129(+) on Treg cells in children with coeliac disease. PMID: 25421756
36. by regulating ATP availability at the cardiac mast cell surface surface, CD39 modulates local renin release and thus, renin-angiotensin system activation, ultimately exerting a cardioprotective effect PMID: 25318477
37. Our data suggests that human bone marrow-derived mesenchymal stem cells can effectively suppress immune responses of the Th17 cells via the CD39-CD73-mediated adenosine-producing pathway PMID: 24043462
38. ecto-nucleotidases CD39 and CD73 are expressed in human endometrial tumors PMID: 24707115
39. FOXP3(+) CD39(+) Treg cells are enriched at the site of inflammation, do not produce proinflammatory cytokines, and are good suppressors of many effector T-cell functions including production of IFN-gamma, TNF, and IL-17F but do not limit IL-17A secretion PMID: 24990235
40. CD39 and CD161 modulate human Th17 responses in CD through alterations in purinergic nucleotide-mediated responses and ASM catalytic bioactivity, respectively. PMID: 25172498
41. The present findings suggest the existence of an endogenous anti-tissue destructive mechanism in gingival tissue via the CD39-adenosinergic axis. PMID: 23941770
42. Results show the interplay between promoter SNPs of CD39 and FAM134B results in an intercellular epistasis which influences the risk of a complex inflammatory disease. PMID: 24970562
43. The data indicates that glioma-derived CD73 contributes to local adenosine-mediated immunosuppression in synergy with CD39 from infiltrating CD4(+)CD39(+) T lymphocytes in human malignant gliomas. PMID: 23737488
44. These data identify CD39 as a novel marker of human regulatory CD8(+) T cells and indicate that CD39 is functionally involved in suppression by CD8(+) Treg cells PMID: 23606272
45. CD39 counteraction inhibits the suppression activity of CD8+ Treg (both from peripheral blood and tumor microenvironment) suggesting that CD39-mediated inhibition constitutes a prevalent hallmark of their function PMID: 23359087
46. hCD39 expressed by circulating leukocytes and intrinsic renal cells limits innate AN injury. PMID: 22684996
47. The expression of ENTPD1 and ecto-adenosine deaminase in lymphocytes of Chagase disease patients are reported. PMID: 22846899
48. We demonstrate for the first time increased CD39 expression and function on circulating microparticles in patients with IPAH. PMID: 22792409
49. identified hitherto unrecognized soluble forms of AK1 and NTPDase1/CD39 that contribute in the active cycling between the principal platelet-recruiting agent ADP and other circulating nucleotides PMID: 22637533
50. These findings not only suggest that CD39 Treg cells may be involved in hepatitis B virus disease progression but also identify CD39 Tregs as a dynamic immune regulatory cell population that may represent a new target of immunomodulatory therapeutic interventions. PMID: 22489829
顯示更多

收起更多
相關疾病：

Spastic paraplegia 64, autosomal recessive (SPG64)
亞細胞定位：

Membrane; Multi-pass membrane protein.
蛋白家族：

GDA1/CD39 NTPase family
組織特異性：

Expressed primarily on activated lymphoid cells. Also expressed in endothelial tissues. Isoform 1 and isoform 3 are present in both placenta and umbilical vein, whereas isoform 2 is present in placenta only.
數據庫鏈接：

HGNC: 3363

OMIM: 601752

KEGG: hsa:953

STRING: 9606.ENSP00000360250

UniGene: Hs.576612

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human